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Background: Hypermethylation in the promoter regions is associated with the suppression of gene expression and
has been considered a potential molecular marker for several tumor types, including head and neck squamous cell
carcinomas (HNSCC).
Methods: To evaluate the gene hypermethylation profile as a prognostic marker, this retrospective study used a
QMSP approach to determine the methylation status of 19 genes in 70 HNSCC patients.
Results: The methylation profile analysis of primary HNSCC revealed that genes CCNA1, DAPK, MGMT, TIMP3 and
SFRP1 were frequently hypermethylated, with high specificity and sensitivity. TIMP3 and CCNA1 hypermethylation
was significantly associated with lower rates of second primary tumor-free survival (p = 0.007 and p = 0.001; log-rank
test, respectively).
Conclusion: This study, for the first time, presents CCNA1 and TIMP3 hypermethylation as a helpful tool to identify
HNSCC subjects at risk of developing second primary carcinomas.
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Head and neck squamous cell carcinomas (HNSCC) are
the sixth most common non-skin cancer in the world,
with an incidence of 600,000 cases per year [1]. Despite
improvements in diagnosis and management of HNSCC
patients, through combined efforts in prevention, sur-
gery, radiotherapy and chemotherapy, a significant per-
centage of patients still have a poor prognosis with a
five-year survival of only 50% [2].
High recurrence and second primary tumor (SPT) rates
are common reasons for HNSCC treatment failure [3,4].
With an incidence of 17-30% and an annual risk of 3-10%
[4-6], the development of SPT significantly contributes to
a worse prognosis and cancer-associated death for HNSCC* Correspondence: andre.vettore@gmail.com
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stated.patients [4,7-10]. The SPT development is in accordance
with the field cancerization theory, which refers to the
presence of malignant or premalignant changes in the en-
tire apparently normal mucosa in response to carcinogen
exposition, especially tobacco and alcohol [11].
Some potential molecular markers have been evaluated
aiming to identify genetic abnormalities associated with a
possible prediction of SPT [12-14]. Aberrant DNA methy-
lation (hypermethylation) of gene promoter region acts as
an alternative to mutations in disrupting tumor suppressor
gene function [15]. This process involves the addition of a
methyl group to the carbon 5 position of the cytosine ring
in CpG dinucleotides catalyzed by DNA methyltransfer-
ases [16]. It is associated with several changes in chroma-
tin structure and the recruitment of proteins to the
methylated sites. The methylation usually leads to the ob-
struction of the promoter region, hindering gene transcrip-
tion and subsequently causing gene silencing [17]. Genes
involved in the cell cycle control, DNA repair, apoptosis,
cell adhesion and signal transduction have already beenLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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tion in different human cancers [18,19] including HNSCC
[20,21]. DNA hypermethylation can be measured in tissue
samples or body fluids using a real-time quantitative
methylation-specific PCR (QMSP) approach. The ability to
quantify methylation allows the delineation of clinically
meaningful threshold values of methylation to improve sen-
sitivity and specificity in the detection of tumor-specific sig-
nal [16,22,23].
We have previously reported that evaluation of methyla-
tion profile in salivary rinses is as an independent prog-
nostic marker for local recurrence-free survival in patients
with HNSCC, justifying the use of DNA hypermethylation
detection in saliva as a tool for identifying and monitoring
HNSCC patients’ subgroups with high risk of presenting
local recurrence [24].
Patients who develop an SPT have a significantly worse
prognosis and increased risk of death by cancer. Thus, the
best strategies to improve patient management are pre-
vention, early diagnosis, an appropriate treatment choice
and close follow-up of patients, with deep investigation of
all suspicious lesions. The feasibility of using molecular
markers able to predict the outcome of HNSCC, through
the evaluation of gene methylation patterns in samples
from HNSCC patients, largely opens the potential for a
better therapy choice and closer surveillance after treat-
ment of the primary tumor. Thus, in this retrospective
study, we sought to characterize the promoter methylation
status of 19 genes in primary tumors from HNSCC pa-
tients, and evaluate its clinical significance and usefulness
as a prognostic biomarker, especially regarding the predic-
tion of the development of second primary tumors in
HNSCC patients.Methods
Patients
This retrospective study involved tissue specimens from
70 HNSCC patients who underwent tumor resection be-
tween 2006 and 2010 at the Department of Head and
Neck Surgery of the A. C. Camargo Hospital (São Paulo,
Brazil). These samples were available at the tumor bank
of the A. C. Camargo Hospital. Only patients diagnosed
with primary HNSCC, not previously treated, that were
over 18 years of age, treated with curative intent and pre-
senting with tumors at oral cavity, larynx, or pharynx were
included in the study. All samples were checked micro-
scopically for the presence of neoplastic tissue and the ab-
sence of contaminating normal mucosa. Tissue samples
were snap-frozen in liquid nitrogen within 30 minutes after
resection and stored at −80°C. For the control group, 60
salivary rinse samples from healthy accompanying patients
(68% men, median age 46.3 and 38% smokers) were col-
lected at the Barretos Cancer Hospital (São Paulo, Brazil).The experimental protocol was approved by the Ethics
Committees of the A. C. Camargo Hospital and per-
formed in accordance with the ethical guidelines of the
1975 Declaration of Helsinki. Clinical-pathological infor-
mation was collected from the patients’ medical records.
Smoking was defined as use of tobacco, chewable or
smoked, for at least 1 year continuously. Alcohol use was
defined as intake of more than 2 alcoholic drinks per day,
for at least 1 year continuously.
Sample collection and DNA extraction
Genomic DNA was isolated from the tissue samples using
the TRIzol reagent (Invitrogen, Frederick, MD) following
manufacturer’s recommendations. Salivary rinses were ob-
tained by swishing and gargling with 10 mL normal saline
solution (NaCl 0.9%). Samples were centrifuged for 10 mi-
nutes at 1,500 rpm, cell pellets were suspended in 300 μL
of water and stored at −70°C. DNA from exfoliated cells
present in salivary rinse was extracted by digestion with
50 mg/mL proteinase K (Invitrogen) in the presence of 1%
SDS at 48°C overnight, followed by phenol/chloroform ex-
traction and ethanol precipitation.
Bisulfite treatment
Bisulfite treatment of DNA converts unmethylated cyto-
sines to uracil, while the methylated ones remain as cy-
tosines. Sodium-bisulfite conversion of 2 μg of DNA was
performed according a previously described method with
modifications [25]. In brief, 2 μg of DNA from each sample
was denatured in 0.2 M NaOH for 20 min at 50°C (in a
total volume of 20 μL). The denatured DNA was diluted in
500 μL of a freshly made bisulfite solution (2.5 M sodium
metabisulfite, 125 mM hydroquinone, 350 mM sodium
chloride, pH5.0) and incubated for 3 h at 70°C in the dark.
Bisulfite-modified DNA was purified using the Wizard
DNA Clean-Up System (Promega) according to the manu-
facturer’s instructions and eluted in 45 μL of water at 80°C.
After treatment with NaOH (final concentration 0.3 M) for
10 min at room temperature, the treated DNA was precipi-
tated by the addition of 75 μL of ammonium acetate, 2.5
volumes of ethanol, and 2 μL of glycogen (5 mg/mL). Each
resulting DNA pellet was washed with 70% ethanol, dried,
dissolved in 110 μL of water, and stored at -80°C.
Target gene selection
A total of 19 genes were selected for the examination of
methylation abnormalities. The panel included genes re-
ported as targets for epigenetic silencing in different hu-
man cancers. All the genes evaluated in this study present
tumor suppressor activities and their silencing could con-
tribute to the tumorigenesis process. Among these genes
are CCNA1, CCND2, CDKN2B, DAPK, DCC, COX2 and
SOCS1 which are involved in cell cycle control and apop-
tosis, CDH1, THBS1 and TIMP3 in cell adhesion, RARβ
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DNA repair, CALCA and MT1G in cell-cell signaling pro-
cesses, HIC1, SFRP1, UCHL1 and HIN1 in cell differen-
tiation and proliferation. It has been shown that the
expression of these genes may be affected by aberrant pro-
moter methylation in association with transcription silen-
cing in different types of human malignancies [20,26-31].Quantitative methylation-specific PCR
The quantitative methylation-specific PCR analyses (QM
SP) were conducted as previously described [32]. Basic-
ally, 30 ng of bisulfite-modified DNA (this is the amount
of material enough to ensure that a methylated sample
will be detected, given the sensitivity thresholds of the
technique) was used as template in fluorogenic QMSP
assays carried out in a final volume of 20 μL in 96-well
plates in the ABI Prism SDS 7500 (Applied Biosystems).
PCR was performed in separate wells for each primer/probe
set and each sample was run in triplicate. The final reac-
tion mixture contained 3 μL of bisulfite-modified DNA,
1.2 μmol/L of forward and reverse primers, 200 nmol/L
of the probe, 0.5U of platinum Taq polymerase (Invitro-
gen), 200 μmol/L dNTPs, 16.6 nmol/L ammonium sul-
fate, 67 mmol/L Trizma, 6.7 mmol/L magnesium chloride
(2.5 mmol/L for CDKN2A), 10 mmol/L mercaptoethanol,
0.1% DMSO, and 1X ROX dye (Invitrogen). PCR was con-
ducted with the following conditions: 95°C for 2 min,
followed by 45 cycles at 95°C for 15 sec. and 60°C for
1 min. Each plate included patient DNA samples, mul-
tiple water blanks and serial dilutions (30–0.0003 ng) of
a positive control allowing the construction of calibration
curves. Leukocyte DNA obtained from a healthy individ-
ual was methylated in vitro using SssI methyltransferase
(New England Biolabs) to generate methylated DNA at all
CpG to be used as positive control.
Primers and probes were obtained from the literature
and specifically amplify the promoter regions of the 19
genes of interest and the internal control gene, ACTB. Pri-
mer and probe sequences are provided in Additional file 1:
Table S1. The relative DNA methylation level of the 19
genes in each sample was determined as a ratio of methy-
lation specific PCR-amplified gene to ACTB and then
multiplied by 100 for easier tabulation (average value of
triplicates of gene of interest divided by the average value
of triplicates of ACTB x 100; reactions presenting standard
deviation of the triplicates greater than 0.5 was repeated).
A cut-off value of ≥0.1% was used to score the samples as
positive ones for the genes CCNA1, MGMT and SFRP1,
while for DAPK and TIMP3, no cut-off values were used,
since these genes were not methylated at all in the saliva
samples evaluated from controls. Cut-off values were used
to optimize sensitivity and specificity levels to better dis-
tinguish HNSCC patients from healthy individuals and toexclude very low-level background readings that can occur
in certain individual for certain genes [18].
Statistical analysis
Statistical analysis was performed using the software
SPSS 19.0 for Windows. Categorical variables were com-
pared using Pearson’s Chi-square test or Fisher’s exact
test, as appropriate. Survival curves were calculated by
Kaplan-Meier method and differences between groups were
compared using the log-rank test. Second primary tumors
were defined according to the criteria proposed by Warren
and Gates [33]. The second primary tumor control time
was defined as the interval between the date of initial treat-
ment and the diagnosis of second primary tumor, while the
overall survival interval was defined as the interval between
the date of initial treatment and the last follow up visit/in-
formation or death. For all analysis we considered statistical
significance when p-value < 0.05.
Results
Patient characteristics and clinical predictors
Seventy HNSCC patients were included in this study
(Table 1). They were mainly male (80%), with ages ranging
from 20 to 90 (median 59 years). Tobacco use or alcohol
consumption (current or past) were found in 87.1% and
82.9%, respectively. Primary tumor sites included: oral
cavity (52.9%), larynx (30%), oropharynx (11.4%), and hy-
popharynx (5.7%). Clinical tumor stage at diagnosis was
cT1/cT2 in 38.6% of the cases and cT3/cT4 in 61.4% of
the cases, and 58.6% of patients presented a clinically posi-
tive lymph node.
Surgery followed by radiotherapy was the treatment
approach in 48.6% of the patients. The median follow up
period for these patients was 29.2 months (range: 1 –
62.6 months). Recurrences occurred in 32 cases (45.7%)
and 7 (10%) patients developed second primary tumors
(SPT) in the upper aerodigestive tract (lung, tongue,
esophagus and lip).
Quantitative methylation-specific PCR in HNSCC samples
Due to the scarcity of DNA quantity after bisulfite treat-
ment of many samples and the number of genes selected, it
would be virtually impossible to evaluate all possible candi-
date genes in all samples. So, we firstly decided to conduct
an exploratory study, and then a more limited set of “best”
genes would be used in an expanded cohort of samples.
The first step was to verify the hypermethylation status of
19 genes in salivary rinse samples collected from healthy in-
dividuals (controls, n = 20). Although tumor and salivary
rinse are not identical tissues, we used this method because
formal biopsy of the 60 noncancer patients was not logistic-
ally feasible and other studies have already shown that sal-
iva is a reliable source of normal mucosa cells [20]. This
analysis showed that TGFβR2, CALCA, HIC1, SOCS1,
Table 1 Demographic and clinical characteristics of
HNSCC patients included in the study (n = 70)
Characteristic N %
Median, range 59.2-90
Age > 60 y.o. 38 54.3
≤ 60 y.o. 32 45.7
Gender Male 56 80.0
Female 14 20.0
Tobacco Yes 61 87.1
Consumption No 9 12.9
Alcohol Yes 58 82.9
Consumption No 12 17.1
Tumor Oral cavity 37 52.9
Site Larynx 21 30.0
Oropharynx 8 11.4
Hypopharynx 4 5.7
cT Stage cT1/cT2 27 38.6
cT3/cT4 43 61.4
cN Stage cN0 29 41.4
cN+ 41 58.6
First curative Surgery 13 18.6
treatment Radiotherapy 3 4.3
Surgery + Radio 34 48.6
Surgery + Radio + Chemo 9 12.9
Radio + Chemo 11 15.7
Second primary Yes 7 10.0
Tumor No 63 90.0
Recurrence Yes 32 45.7
No 38 54.3
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CCND2, MT1G and DCC were frequently methylated
in control samples, showing low specificity (Table 2).
Therefore, these 14 genes were excluded from the study.
The methylation pattern of the remaining 7 genes, identi-
fied as unmethylated in control samples, was profiled in 20Table 2 Comparison of hypermethylation detection on HNSC
rinse samples
Genes Control
Cases (n) M n (%) Cases (n)
CCNA1 60 2 (3) 67
DAPK 39 1 (3) 68
MGMT 57 2 (4) 67
SFRP1 20 0 (0) 58
TIMP3 60 2 (3) 70
M – Methylated.HNSCC specimens. This analysis revealed that hyperme-
thylation of CCNA1, DAPK, MGMT, SFRP1 and TIMP3
was frequent in head and neck tumor (40-70%). So, these
5 genes that could better distinguish HNSCC tumors from
control samples were selected to be tested in the expanded
cohort of HNSCC specimens (n = 70) and control subjects
(n = 60).
By the end, CCNA1 was found methylated in 33% of
HNSCC cases, DAPK in 51%, MGMT in 21%, SFRP1 in
62% and TIMP3 in 53% (Table 2, Figure 1). Noteworthy,
complete coverage of every sample for every possible
methylation marker selected was not possible due to either
low quantity of total extracted DNA or limited DNA
amount after bisulfite treatment. So, all the genes could not
be run on all samples because of lack of DNA. This analysis
demonstrated these genes as able to distinguish HNSCC
tumors from control samples with high specificity (>96%)
and sensitivity (21-62%) (Table 2). Furthermore, 54 HNSCC
samples (77.1%) showed hypermethylation in at least one of
these five genes.Association between aberrant methylation and
patient characteristics
The methylation pattern of CCNA1, DAPK, MGMT, SFRP1
and TIMP3 as well as a panel containing all these 5 genes
was analyzed for potential associations with clinical and
pathological characteristics of HNSCC patients, including
age, gender, tobacco consumption, alcohol consumption,
primary tumor site, T stage, N stage, lymph vascular inva-
sion, perineural invasion, surgical margins status, lymph
node involvement and second primary tumor development.
This analysis showed that the hypermethylation of CC
NA1 (p = 0.007) and SFRP1 (p = 0.024) was associated
with age greater than 60 years old, while the hypermethy-
lation of TIMP3 was associated with hypopharynx tumors
(p = 0.023; Table 3). Furthermore, aberrant methylation of
CCNA1 and TIMP3 was significantly correlated to the de-
velopment of SPT (p = 0.004 and p = 0.012, respectively).
Of the 7 patients who developed SPT, 86% (6/7) had
CCNA1 methylated, while 100% showed TIMP3 methyla-
tion (Table 3). There was no other significant associationC tumor specimens and normal control salivary
HNSCC Specificity%
(95% CI)
Senstivity%
(95% CI)M n (%)
22 (33) 97 (93–101) 33 (21–45)
35 (51) 97 (93–101) 51 (38–64)
14 (21) 96 (91–101) 21 (11–31)
36 (62) 100 62 (50–74)
37 (53) 97 (93–101) 53 (40–66)
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Figure 1 The methylation rates of five genes (CCNA1, TIMP3, DAPK, MGMT and SFRP1) in normal controls and HNSCC samples. x-axis,
proportion of methylated cases/tested cases; y-axis, quantity of hypermethylation (gene of interest/ACTB × 100).
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logical characteristics of HNSCC patients.
Overall survival at 3 years was 47%. No statistical signifi-
cance was observed on the overall survival according to
gender, tumor site and tobacco and alcohol use. But, as
expected, the overall survival was better for those patients
with early T stage (63.0% initial vs. 36.8% advanced, p =
0.010) and negative N stage (64.9% negative vs. 34.4%
positive, p = 0.001). No significant association was found
between any other clinical markers and overall survival
rates (Additional file 2: Table S2).
The analyses of overall survival were not able to identify
any significant associations with the hypermethylation sta-
tus of the five investigated genes in the HNSCC cases
(Table 4), but, given the association between CCNA1 and
TIMP3 hypermethylation and the development of SPT,
the second primary tumor-free survival at 3-years was also
evaluated (Table 4). Notably, HNSCC patients carrying tu-
mors with methylated versions of CCNA1 and TIMP3
genes experienced an increased probability of developing
SPT in comparison to patients whose tumors presentedunmethylated versions of these two genes (CCNA1: 38.0%
methylated vs. 2.2% unmethylated, p = 0.001; and TIMP3:
25.1% methylated vs. 0% unmethylated, p = 0.007; log-rank
test; Figure 2). A significantly higher risk of developing
second primary tumors was observed for patients carrying
tumors with methylated CCNA1 (HR = 13.95, 95% CI =
1.67-116.33; p = 0.015), but the same was not observed for
methylated TIMP3 tumors (HR = 68.62, 95% CI = 0.15-
30191.20; p = 0.173). The independent effect of CCNA1
methylation and significant clinical features on the prob-
ability of second primary tumor development was analyzed
using a Cox regression model. This multivariate analysis
was not able to detect any independent factor.
Discussion
The treatment approach and consequently the prognosis of
HNSCC patients is mainly determined by the stage at pres-
entation through the evaluation of the tumor extent, the
presence of lymph-node and distant metastases and several
histopathological parameters evaluated after surgery. Disap-
pointingly, despite the evolution in patient management,
Table 3 Correlation between clinical and pathological characteristics of HNSCC patients and aberrant methylation profile of CCNA1, DAPK, MGMT, SFRP1, TIMP3
and the 5-gene panel in HNSCC samples
Characteristics Category CCNA1 p-value DAPK p-value SFRP1 p-value TIMP3 p-value 5-gene panel p-value
U M U M U M U M U M
Age < 60 yrs 30 (81) 7 (19) 0.007 20 (53) 18 (48) 0.446 17 (50) 17 (50) 0.024 22 (56) 17 (44) 0.081 13 (34.2) 25 (65.8) 0.016
> 60 yrs 15 (50) 15 (50) 13 (43) 17 (57) 5 (21) 19 (79) 11 (36) 20 (64) 3 (9.7) 28 (90.3)
Tumor site Oral cavity 26 (74) 9 (26) 0.530a 20 (56) 16 (44) 0.609a 15 (50) 15 (50) 0.055a 23 (62) 14 (38) 0.023a 9 (25.0) 27 (75.0) 0.419
Larynx 13 (62) 8 (39) 8 (38) 13 (62) 5 (29) 12 (71) 7 (33) 14 (64) 6 (28.6) 15 (71.4)
Oropharynx 4 (57) 3 (43) 3 (43) 4 (57) 0 (0) 7 (100) 1 (13) 7 (87) 0 (0) 8 (100)
Hypopharynx 2 (50) 2 (50) 2 (50) 2 (50) 2 (50) 2 (50) 2 (50) 2 (50) 1 (25) 3 (75)
Second primary tumor Absent 44 (73) 16 (27) 0.004a 31 (51) 30 (49) 0.429a 21 (41) 30 (59) 0.235a 33 (52) 30 (48) 0.012a 16 (25.8) 46 (74.2) 0.188a
Present 1 (14) 6 (86) 2 (29) 5 (71) 1 (14) 6 (86) 0 (0) 7 (100) 0 (0) 7 (100)
U – unmethylated, n (%); M – methylated, n (%), a – p-value calculated by Fisher’s Exact Test. Numbers in bold number reflect statistically significant associations.
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Table 4 3-year overall survival and SPT-free survival rates
according to the methylation status of the five selected
genes and the 5-gene panel
Variables Methylation
status
Overall
survival (%)
p SPT-free
survival (%)
p
CCNA1 U 50.2 0.578 97.8 0.001
M 34.5 62.0
DAPK U 46.3 0.914 94.1 0.292
M 45.7 79.7
MGMT U 44.4 0.714 88.5 0.527
M 48.2 77.4
SFRP1 U 43.1 0.494 91.7 0.160
M 43.9 79.1
TIMP3 U 52.8 0.183 100 0.007
M 40.5 74.9
5-gene panel U 48.2 0.176 100 0.091
M 38.9 81.4
SPT, Second Primary Tumor; U – unmethylated; M – methylated. Numbers in
bold number reflect statistically significant associations.
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in recent decades [34]. In HNSCC, late diagnosis and the
development of loco-regional recurrences are responsible
for the poor prognosis observed. Besides them, another
common reason for treatment failure in HNSCC cases
is the development of second primary tumors (SPT) [4].
HNSCC patients show a 10–30 times greater chance of de-
veloping SPT [35].
In order to identify new molecular markers for progno-
sis of HNSCC patients, we used QMSP to assess the
methylation status of 19 genes in HNSCC samples col-
lected during surgical treatment. CCNA1, DAPK, MGMT,
SFRP1 and TIMP3 were found frequently and specifically
methylated in HNSCC specimens.
A small number of studies have reported a relatively fre-
quent hypermethylation of these genes in HNSCC [36-46].
According to them, CCNA1 methylation could be detected
in 34-53% of HNSCC cases evaluated in three studies,
while DAPK gene methylation was detected in 21-74% of
tumors examined by six studies. MGMT hypermethylation
was detected in 22-50% of tumors examined by four inde-
pendent research groups, SFRP1 was methylated in 24-
35% of tumors examined in two different studies and
TIMP3 methylation was detected in 10-72% of tumors
evaluated in two studies. Consistent with this, we also
found CCNA1 (33%), DAPK (51%), MGMT (21%) and
TIMP3 (53%) frequently methylated in HNSCC samples.
In contrast, we were able to detect SFRP1 methylation in
62% of the HNSCC samples, a frequency higher than ob-
served previously.
To our knowledge, this is the first study to show a
significant association between the presence of TIMP3
and CCNA1 aberrant methylation in the primary HNcarcinomas and the development of SPT. Tissue inhibitor
of metalloproteinases 3 (TIMP3) belongs to a family of
genes that inhibit matrix metalloproteinases (MMPs), a
group of peptidases involved in degradation of the extra-
cellular matrix (ECM). TIMP3 exerts its anti-proteolytic
function either at the invasion front of an infiltrating
tumor to quench tumor-associated ECM degrading activ-
ity or in the stroma itself, where soluble proteases liberate
ECM-tethered factors that assist the cancer cell in migra-
tion and invasion. Numerous studies have indicated that
TIMPs inhibit cellular invasion, tumorigenesis, metastasis
and angiogenesis [47]. Therefore, the hypermethylation of
TIMP3 and, consequently, its transcriptional repression
would hinder its function as inhibitors of matrix metallo-
proteinases (MMPs), thus contributing to the degradation
of the extracellular matrix. A previous study [48] reported
that an increased expression ofMMP9 in the histologically
negative surgical margins of HNSCC was associated with
the development of SPT. MMP9 encodes a gelatinase that
degrades type IV collagen, the major constituent of base-
ment membrane. The lateral spread of clones from malig-
nant tumors involves the occurrence of multiple factors
necessary for cell motility to penetrate the extracellular
matrix [49]. Thus, the inhibition of TIMP3 by hyperme-
thylation and, consequently, the loss of the regulating ac-
tivity of the MMP extracellular matrix degradation may
contribute to the development of SPT. Sun et al. [50]
showed the detection of TIMP3 hypermethylation in saliv-
ary rinse samples collected at diagnoses associated with
local recurrence-free survival in patients with HNSCC. In
a recent study, our group demonstrated that the detection
of TIMP3 hypermethylation in salivary rinse collected, not
only at diagnosis, but also six months after the last cura-
tive treatment is an independent prognostic factor for
HNSCC patients [24].
The protein encoded by cyclin A1 (CCNA1) belongs to
the highly conserved cyclin family, whose members are
characterized by a dramatic periodicity in protein abun-
dance through the cell cycle. Cyclins function as regula-
tors of CDK kinases. CCNA1 cyclin was found to bind to
important cell cycle regulators, such as Rb family proteins,
transcription factor E2F-1, and the p21 family proteins
[51,52]. A previous study found promoter hypermethyla-
tion of the cyclin A1 gene in 45% of primary HNSCC tis-
sue samples evaluated, as well as in multiple cell lines.
Rivera et al. [53] could show that CCNA1 is a downstream
target of p53 and it can induce apoptosis and G2M arrest
if up-regulated. We sought that loss of CCNA1 expression
though promoter hypermethylation might be involved in
early oncogenic events, down regulating apoptosis and cell
cycle arrest, therefore contributing to a proliferative ad-
vantage to cells in precursor lesions and giving rise to
the expansion of a clonal population of progenitor cells
susceptible to new oncogenic events. These lesions can
Figure 2 Kaplan-Meier curve comparing the probability of second primary tumor development in patients carrying methylated or
unmethylated versions of CCNA1 (A) and TIMP3 (B) in HNSCC samples.
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ment of SPT.
Although the presence of fields with a high risk of devel-
opment of second primary tumors is indicated by certain
clinical lesions such as erythroplakia and leukoplakia [54],
most premalignant fields are not clinically detectable and
others can extend well beyond the clinically visible area
[55,56]. Previous studies have already supported the the-
ory of field cancerization, which refers to the presence of
malignant or premalignant changes in the entire field of
apparently normal tissue adjacent to the tumor in re-
sponse to a carcinogen exposition [11]. According to this
theory, the development of SPT represents the progres-
sion of multiple separate genetically altered mucosal foci.
However, recent studies have been reporting that at least a
proportion of these SPT arise from residual portions of a
single contiguous preneoplastic field after the complete
resection of the index tumor. According to them, a stem
cell acquires genetic alterations and forms a patch with
genetically altered daughter cells. As a result of subse-
quent genetic alterations, the stem cell escapes normal
growth control, gains growth advantage, and develops into
an expanding clone. The lesion laterally displaces the nor-
mal epithelium and additional genetic hits give rise to
various subclones within the field. Different clones diverge
at a certain point with respect to genetic alterations but
do share a common clonal origin, and as a result of the
process of clonal divergence and selection, eventually a
subclone evolves into invasive cancer [57]. Our results
suggest that some of these genetic alterations could be the
aberrant methylation of CCNA1 and TIMP3 genes. Along
the same line, our group has also demonstrated that the
overexpression ofMMP9 in histologically negative HNSCC
margins was significantly correlated to a high risk of devel-
oping SPT [48].
Conclusions
In summary, our results showed that CCNA1, DAPK,
MGMT, SFRP1 and TIMP3 are frequently and specific-
ally hypermethylated in HNSCC samples. In spite of the
small number of samples evaluated, we demonstrated
for the first time that the hypermethylation of CCNA1
and TIMP3 are significantly correlated to the development
of SPT. Based on these results, we may speculate that the
methylation pattern of these genes in HNSCC, could be a
helpful marker for the identification of subjects at risk of
new neoplastic evolution. Of note, the confidence inter-
vals observed in the analyses of hazard ratios are large and
this may be due to the small sample size evaluated. Des-
pite of this, the statistically significance observed in the as-
sociation through the log-rank analyses for both genes
and in the Cox regression for CCNA1 and STP denotes
the potential of these markers as clinically relevant. The
possibility of evaluating the primary tumor to predict therisk for the development of second primary tumors is rele-
vant given the difficulty of identifying premalignant fields
in the upper aerodigestive tract and the fact that the whole
mucosa would have to be assessed, representing a very
invasive diagnostic method. Further validation of these re-
sults requires studies with larger patient groups and lon-
ger follow-up period, but by achieving a good predictive
negative value, this QMSP approach could constitute an
alternative in predicting the risk for the development of
SPT, allowing the use of preventive measures, with more
frequent clinical monitoring of these patients and maybe
select patients candidates for adjuvant treatment.
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